New pill for tough blood cancers enters first human tests

NCT ID NCT07619287

Recruiting now Disease control Sponsor: BeOne Medicines Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 9 times

Summary

This early-phase trial is testing a new oral drug called BG-75202, alone or with another medicine, in about 118 adults with myeloid blood cancers that have come back or not responded to prior treatment. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrink tumors. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BG-75202 (a KAT6A/B inhibitor taken orally, alone or with another drug)
What this could lead to: If it works, this could point toward a new treatment option for certain blood cancers that have not responded to prior therapy.
What could go wrong: This is a very early Phase 1 trial with only 118 participants. The main goal is safety, not proof of effectiveness. Many early-stage drugs fail to show benefit or have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOID MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOID MALIGNANCY

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Auckland City Hospital
RECRUITING

Auckland, 1023, New Zealand
Concord Repatriation General Hospital
RECRUITING

Concord, New South Wales, NSW 2139, Australia
Icon Cancer Centre Kurralta Park
RECRUITING

Kurralta Park, South Australia, SA 5037, Australia
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch
RECRUITING

Tianjin, Tianjin Municipality, 301617, China
Linear Clinical Research
RECRUITING

Nedlands, Western Australia, WA 6009, Australia
St George Hospital
RECRUITING

Kogarah, New South Wales, NSW 2217, Australia
The First Affiliated Hospital of Nanchang University Branch Donghu
RECRUITING

Nanchang, Jiangxi, 330006, China
The First Affiliated Hospital of Nanchang University Branch Xianghu
RECRUITING

Nanchang, Jiangxi, 332000, China
The First Hospital of Lanzhou University
RECRUITING

Lanzhou, Gansu, 730000, China
The Second Hospital of Hebei Medical University
RECRUITING

Shijiazhuang, Hebei, 050000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.